Crispr Therapeutics is a biotechnology business based in the US. Crispr Therapeutics shares (CRSP.US) are listed on the NASDAQ and all prices are listed in US dollars. Its last market close was $55.65 – a decrease of 1.35% over the previous day. Crispr Therapeutics employs 407 staff and has a trailing 12-month revenue of around $371.2 million.
Only you can make the decision on the time to leap... but here's some supporting information and analysis.
Over the last 12 months, Crispr Therapeutics's shares have ranged in value from as little as $37.55 up to $91.1. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Crispr Therapeutics's is 1.743. This would suggest that Crispr Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Historical closes compared with the last close of $55.65
| 1 week (2024-04-17) | -0.91% |
|---|---|
| 1 month (2024-03-24) | -21.71% |
| 3 months (2024-01-24) | -11.48% |
| 6 months (2023-10-24) | 42.04% |
| 1 year (2023-04-24) | 12.58% |
| 2 years (2022-04-24) | -2.83% |
| 3 years (2021-04-22) | -56.03% |
| 5 years (2019-04-24) | 40.67% |
The gauge below shows real-time ratings that are based on 26 popular indicators such as moving averages, for specific time periods. It's not a recommendation but is simply technical analysis that can form part of your research.
Finder might not agree with the analysis and we take no responsibility. We also give no representations or warranty on the accuracy or completeness of the information provided on this page.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Steps to owning and managing ZTEK, with 24-hour and historical pricing before you buy.
Steps to owning and managing MYNZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing ATAI, with 24-hour and historical pricing before you buy.
Steps to owning and managing OWLT, with 24-hour and historical pricing before you buy.
Steps to owning and managing LLY, with 24-hour and historical pricing before you buy.
Steps to owning and managing HUM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ILMN, with 24-hour and historical pricing before you buy.
Steps to owning and managing UNH, with 24-hour and historical pricing before you buy.
Steps to owning and managing PFE, with 24-hour and historical pricing before you buy.
Steps to owning and managing JNJ, with 24-hour and historical pricing before you buy.